AURORA, Colo.–(BUSINESS WIRE)–Ocugen, Inc. today announced leadership updates and that company Chairman and CEO Dr. Shankar Musunuri will present at BIO International Convention this week in Philadelphia.
Category: Business
Glaukos Corporation Announces Launch of Initial Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced tod…
Research and Markets: Ocular Hypertension – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jrdqcj/ocular) has announced the addition of the “Ocular Hypertension – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive inf…
LENSAR erhält CE-Kennzeichnung für fünf neue Leistungsanwendungsupgrades am LENSAR-Lasersystem
ORLANDO, Florida (USA)–(BUSINESS WIRE)–LENSAR Inc., ein globaler Führer in der Femtosekunden-Lasertechnologie für refraktive Kataraktchirurgie, hat heute mitgeteilt, dass es für eine Suite aus fünf neuen Anwendungstechnologien, die in das Vorzeigeprodukt des Unternehmens, das LENSAR® Laser System, integriert wurden, die CE-Kennzeichnung der Regulierungsbehörde der Europäischen Union erhalten hat. Als erste Femtosekunden-Laserkataraktplattform zur Ermöglichung der Automatisierung von Planungs-
LENSAR obtient le marquage CE pour cinq nouvelles mises à niveau d’application de performance du système laser LENSAR
ORLANDO, Floride–(BUSINESS WIRE)–LENSAR, Inc., un leader mondial en technologie laser femtoseconde de prochaine génération pour la chirurgie de la cataracte réfractive, a annoncé aujourd’hui que les régulateurs de l’Union européenne lui avaient accordé le marquage CE pour une série de cinq nouvelles technologies d’application intégrées au produit phare de la société, le système laser LENSAR®. En tant que première plateforme de cataracte laser femtoseconde à permettre l’automatisation des élém
LENSAR Receives CE Mark for Five New Performance Application Upgrades to the LENSAR Laser System
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., announces receipt of the CE Mark for five application upgrades to the LENSAR® Laser System with Streamline™ for femtosecond cataract surgery.
Riassunto: LENSAR riceve il marchio CE per cinque nuovi aggiornamenti alle prestazioni dell’applicazione per il sistema laser LENSAR
ORLANDO, Florida–(BUSINESS WIRE)–LENSAR, Inc., leader a livello mondiale della tecnologia laser a femtosecondi di nuova generazione per la chirurgia refrattiva per cataratta, ha annunciato oggi di aver ricevuto il marchio CE da parte degli enti regolatori dell’Unione Europea per un pacchetto di cinque nuove tecnologie di applicazione integrate nel prodotto fiore all’occhiello della società, il sistema laser LENSAR®. Il testo originale del presente annuncio, redatto nella lingua di partenza, è
Research and Markets: Global Ophthalmics Partnering Deal Trends, Players and Financials 2010-2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/pftvgh/global) has announced the addition of the “Global Ophthalmics Partnering 2010-2015: Deal trends, players and financials” report to their offering. The Glob…
InSite Vision to Merge With Canadian Biotechnology Company QLT
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB: INSV) today announced that it has reached a definitive agreement with QLT Inc. (NASDAQ: QLTI) (TSX: QLT) under which QLT will acquire InSite in an all-stock transaction that will create an ophthalmic specialty pharmaceutical company with a diversified portfolio of products, full R&D capabilities and innovative platform technologies. The transaction is expected to drive shareholder value by accelerating both companies’ development
QLT Announces Multiple Transactions Designed to Transform the Company and Create Significant Near- and Long-Term Value for Shareholders
VANCOUVER, British Columbia–(BUSINESS WIRE)–QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT” or the “Company”) announced today that it has signed definitive agreements on multiple separate transformative transactions and will be returning capital to shareholders. Together, these actions are expected to create significant liquidity and near- and long-term value for QLT shareholders. InSite Vision Acquisition: QLT has entered into a definitive agreement to acquire (the “InSite Acquisition”) InSite Visio
Company Profile for Acucela Inc.
–(BUSINESS WIRE)–Acucela Inc. is a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, which could impact mi…
Avedro Announces 500th Cross-linking Device Sale Outside the US
WALTHAM, Mass.–(BUSINESS WIRE)–Avedro announces that it has sold its 500th cross-linking device outside of the United States. Study data presented on its non-surgical PiXL procedure shows promise for low myopia correction.
Terry Walsh Joins Renaissance as National Director of Sales and Market Development
INDIANAPOLIS–(BUSINESS WIRE)–Renaissance, a leading ancillary insurance carrier of customizable dental and vision plans, has hired industry veteran Terry Walsh as national director of sales and market development.
Ocata Therapeutics Receives Important New U.S. Patent for its RPE Therapy for Macular Degenerative Diseases
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the scope of protection covering its retinal pigment epithelium (RPE) transplant technology with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,045,732. This new patent further strengthens the Company’s comprehensive suite of intellectual property which
EYE TECH CARE Launches Its Operations in China as Part of Its International Expansion
RILLIEUX-LA-PAPE, France–(BUSINESS WIRE)–EYE TECH CARE launches its operations in China as part of its international expansion.
EYE TECH CARE Launches Its Operations in China as Part of Its International Expansion
RILLIEUX-LA-PAPE, France–(BUSINESS WIRE)–EYE TECH CARE launches its operations in China as part of its international expansion.
Tyrogenex X-82 Poster Presentation at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting
PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a leader in the development of novel kinase inhibitors to target angiogenesis, announced that the University of Wisconsin presented a new trial concept of X-82 poster at ASCO in Chicago.
Research and Markets: Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/mn2tbt/keratoconjunctivit) has announced the addition of the “Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2015” report to their offering. This repo…
Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in
Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that the United States Patent and Trademark Office (USPTO) issued three new U.S. Patents, Nos. 9,040,770, 9,040,039 and 9,040,038, which expand the scope of protection of the four previously issued U.S. patents covering its retinal pigment epithelium (RPE) transplant technology. These three new patents extend protection to